Testing new antibiotic for resistant Klebsiella infections
Part of Infections clinical trials.
This study looks at how well a new antibiotic (cefiderocol) works against a tough type of Klebsiella pneumoniae bacteria that is resistant to many other antibiotics. It may help find better treatments for serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed Klebsiella pneumoniae infection (a type of bacteria).
- You must not have taken any antibiotics in the 48 hours before your sample was collected.
- You must have a sample (blood, urine, sputum, or wound) that can be tested.
- Your medical records must be complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for infections caused by a resistant bacteria called Klebsiella pneumoniae. It aims to see how well this drug works against these hard-to-treat infections.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at how Klebsiella pneumoniae bacteria that are resistant to many antibiotics form a protective layer (biofilm) and pump out drugs (efflux pump activity). By understanding these mechanisms, doctors may find better ways to treat these tough infections.
This study looks at whether a rapid test can help doctors detect CPE bacteria (which are resistant to many antibiotics) sooner, and whether using infection control measures can stop these bacteria from spreading. It may help you get the right care and reduce the risk of infection while in the hospital.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
Hear when a new Carbapenem-resistant Hypervirulent Klebsiella Pneumoniae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.